Calithera Biosciences Earnings Date & Estimates

Calithera Biosciences (NASDAQ:CALA) was a clinical-stage biotechnology company focused on developing small-molecule therapies that target cancer metabolism. The company’s research centered on metabolic pathways that tumors use to support growth and survival, with the goal of improving outcomes for patients with cancer.

Its lead investigational product was telaglenastat (CB-839), an oral inhibitor of glutaminase, an enzyme involved in glutamine metabolism. Calithera evaluated telaglenastat in combination with other treatments for cancers including renal cell carcinoma, triple-negative breast cancer and hematologic malignancies. The company also developed CB-280, an investigational arginase inhibitor intended for potential use in solid tumors.

Founded in 2010 and based in South San Francisco, California, Calithera conducted clinical-development activities primarily in the United States, with research and collaborations involving international pharmaceutical companies. Susan Molineaux, a co-founder, served as the company’s president and chief executive officer for much of its operating history. Calithera later discontinued development activities and ceased operating as an active biotechnology company.